IDEAYA Biosciences, Inc. (IDYA) 股票分析

公司概述

IDEAYA Biosciences, Inc. operates as a precision medicine oncology company that discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics within the United States. The enterprise functions within the healthcare sector, specifically focusing on the biotechnology industry, where it leverages molecular diagnostics to identify specific patient subsets for its novel drug candidates. Currently, the company employs a workforce of 145 individuals and holds a market capitalization of $2.72B, while reporting trailing twelve-month revenue of $218.71M. These valuation and revenue figures position IDEAYA as a significant entity in the biotechnology landscape, indicating substantial market interest despite the company's current profitability challenges inherent in the early-stage development phases of oncology therapeutics like Darovasertib. The scale of the market cap relative to the revenue base suggests a premium valuation often associated with high-growth potential biotech firms that prioritize R&D investment over immediate profit generation.

财务健康

The company reported revenue of $218.71M for the trailing twelve months, yet incurred a net income of $-113,698,000 and an EBITDA of $-156,612,992, revealing a significant structural gap where operating expenses and R&D costs substantially exceed revenue generation. This disparity results in a free cash flow of $-52,472,624, which indicates that the company is consuming its liquid assets to fund operations and development activities rather than generating cash reserves. The gross margin stands at -43.9%, reflecting high production or development costs relative to sales, while the operating margin is -869.5% and the profit margin is -52.0%, illustrating the extreme cost intensity typical of biotechnology firms scaling up clinical trials. Despite these negative margins, the balance sheet shows a cash position of $639.39M against total debt of $27.91M, with a debt-to-equity ratio of 2.73, suggesting a leveraged capital structure that relies heavily on equity financing or cash reserves to manage obligations. The current ratio is an exceptionally high 11.34, indicating robust short-term liquidity and a strong ability to cover immediate liabilities with available current assets. Furthermore, the return on equity is -10.9% and the return on assets is -8.9%, metrics that reveal that management is currently generating losses on the deployed capital base, a common characteristic for companies in the growth phase of the biotech lifecycle before product approvals and commercialization yield positive returns.

估值评估

The trailing P/E ratio is listed as N/A due to negative earnings, while the forward P/E is -9.13, implying that the market anticipates a return to profitability or that the negative earnings are expected to persist in the near term. The price-to-book ratio is 2.66, indicating that the market values the company at a significant premium over its book value, likely reflecting the intangible value of its drug pipeline and intellectual property. Alternative valuation metrics such as the price-to-sales ratio of 12.45 and an EV/EBITDA of -13.48 suggest that investors are pricing the stock based on future revenue potential rather than current earnings power or cash flow generation. The 52-week trading range spans from a low of $13.45 to a high of $39.28, and without the current specific share price provided in the facts, the precise percentage deviation from the 52-week high cannot be calculated, though the wide range demonstrates significant historical price volatility. The beta value of 0.02 is exceptionally low, suggesting that the stock price exhibits minimal volatility relative to the broader market and does not move significantly in tandem with general market indices.

Growth & Income

The company experienced a revenue growth rate of 55.4% year-over-year, while the earnings growth rate is N/A due to negative net income, indicating that top-line expansion is currently outpacing any potential earnings recovery. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, IDEAYA reinvests all available capital and retained earnings directly into research and development, clinical trials, and commercialization efforts rather than distributing income to shareholders. This reinvestment strategy is standard for biotechnology companies in the development stage, where funding pipeline progression is prioritized over income generation for investors. The overall growth and income profile is characterized by rapid top-line expansion funded by existing cash reserves, with no current reliance on dividend income, positioning the company as a pure-play growth investment dependent on future commercial success of its oncology portfolio.